E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Bioactivity-focused Semi-synthesis in Drug Discovery"

Quicklinks

A special issue of Molecules (ISSN 1420-3049).

Deadline for manuscript submissions: closed (30 October 2013)

Special Issue Editor

Guest Editor
Dr. Attila Hunyadi (Website)

Institute of Pharmacognosy, Faculty of Pharmacy, University of Szeged, Eötvös u. 6, 6720 Szeged, Hungary
Phone: +3662546456
Fax: +3662545704
Interests: natural product chemistry, including isolation, structure elucidation and semi-synthetic modification of bioactive plant constituents, primarily of ecdysteroids and flavonoids; natural compounds of potential anticancer or multi-drug resistance decreasing activity; compounds, that exert selective activity against MDR cancer; bioactivity-focused semi-synthesis of natural compounds

Special Issue Information

Dear Colleagues,

Thanks to millions of years of co-evolution between micro-organisms, plants and animals, Nature is a treasure mine of small molecules with potential for therapeutic drug discovery. By providing highly complex patterns of interactions with the various biochemical processes of other organisms, many secondary plant metabolites are easily recognized for their crucial role in the plants’ adaptation to their environment. An overview of which sources have yielded newly approved drugs the past 30 years clearly shows the success of utilizing Nature’s chemical complexity (Newman & Cragg 2012) inasmuch as the majority of these new drugs originated from a natural source or were designed on the basis of natural scaffolds. Dominancy of Nature-originated compounds is particularly true for antibacterial and anticancer drugs. On the other hand, very few natural leads pass through the drug development process per se. Various semi-synthetic modifications or designing synthetic analogs are usually needed for optimizing activity profile and bioavailability, and for decreasing unwanted side-effects and toxicity in order to meet the strict criteria for a modern therapeutic agent.
The present special issue of Molecules is dedicated to outstanding research and review papers within the scope of natural product based drug discovery via semi-synthetic approaches. Communications of any chemical modification of natural products are considered for publication as long as bioactivity is the focus of the work: manuscripts reporting optimization of pharmacodynamic and/or pharmacokinetic properties, decreasing toxicity, preparation of pro-drugs or even changing the biological target(s) of natural products are welcome. Preparation and investigation of semi-synthetic compound libraries from chemically engineered extracts is considered as an emerging area of the field which certainly also falls within the scope of this issue. Manuscripts may review reactions of certain typical natural scaffolds, biological significance of the products, or options that introduce selected moieties onto various natural skeletons in order to influence bioactivity. Authors of review papers are kindly requested to make a pre-submission inquiry with a brief outline to the guest editor.

Dr. Attila Hunyadi
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs).


Keywords

  • natural product based drug discovery
  • rational drug design
  • biomedical engineering
  • isolation and chemical modification
  • semi-synthesis
  • bioactivity optimization
  • side-effect profile improvement
  • toxicity decrease
  • pharmacodynamics
  • pharmacokinetics
  • ADME
  • bioavailability
  • pro-drug

Published Papers (3 papers)

View options order results:
result details:
Displaying articles 1-3
Export citation of selected articles as:

Research

Open AccessArticle Anticancer and Multidrug Resistance-Reversal Effects of Solanidine Analogs Synthetized from Pregnadienolone Acetate
Molecules 2014, 19(2), 2061-2076; doi:10.3390/molecules19022061
Received: 9 December 2013 / Revised: 29 January 2014 / Accepted: 6 February 2014 / Published: 17 February 2014
Cited by 8 | PDF Full-text (453 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
A set of solanidine analogs with antiproliferative properties were recently synthetized from pregnadienolone acetate, which occurs in Nature. The aim of the present study was an in vitro characterization of their antiproliferative action and an investigation of their multidrug resistance-reversal activity on [...] Read more.
A set of solanidine analogs with antiproliferative properties were recently synthetized from pregnadienolone acetate, which occurs in Nature. The aim of the present study was an in vitro characterization of their antiproliferative action and an investigation of their multidrug resistance-reversal activity on cancer cells. Six of the compounds elicited the accumulation of a hypodiploid population of HeLa cells, indicating their apoptosis-inducing character, and another one caused cell cycle arrest at the G2/M phase. The most effective agents inhibited the activity of topoisomerase I, as evidenced by plasmid supercoil relaxation assays. One of the most potent analogs down-regulated the expression of cell-cycle related genes at the mRNA level, including tumor necrosis factor alpha and S-phase kinase-associated protein 2, and induced growth arrest and DNA damage protein 45 alpha. Some of the investigated compounds inhibited the ABCB1 transporter and caused rhodamine-123 accumulation in murine lymphoma cells transfected by human MDR1 gene, expressing the efflux pump (L5178). One of the most active agents in this aspect potentiated the antiproliferative action of doxorubicin without substantial intrinsic cytostatic capacity. The current results indicate that the modified solanidine skeleton is a suitable substrate for the rational design and synthesis of further innovative drug candidates with anticancer activities. Full article
(This article belongs to the Special Issue Bioactivity-focused Semi-synthesis in Drug Discovery)
Open AccessArticle Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines
Molecules 2014, 19(2), 2077-2088; doi:10.3390/molecules19022077
Received: 31 October 2013 / Revised: 21 January 2014 / Accepted: 29 January 2014 / Published: 17 February 2014
Cited by 6 | PDF Full-text (506 KB) | HTML Full-text | XML Full-text
Abstract
Advanced small cell lung cancer (SCLC) has a dismal prognosis. Modulation of the camptothecin topotecan, approved for second-line therapy, may improve response. Our recent finding of synergistic enhancement of the cytotoxic activity of camptothecin (CPT) by cyclin-dependent kinase 4 inhibitors is extended [...] Read more.
Advanced small cell lung cancer (SCLC) has a dismal prognosis. Modulation of the camptothecin topotecan, approved for second-line therapy, may improve response. Our recent finding of synergistic enhancement of the cytotoxic activity of camptothecin (CPT) by cyclin-dependent kinase 4 inhibitors is extended here to a panel of camptothecin analogs comprising 10-hydroxy-CPT (HOCPT), topotecan (TPT; 9-[(dimethylamino)-methyl]-10-hydroxy-CPT), 9-amino-CPT (9AC), 9-nitrocamptothecin (rubitecan), SN38 (7-ethyl-10-hydroxycamptothecin) and 10-hydroxy-9-nitrocamptothecin (CPT109) in combination with PD0332991, CDK4I, roscovitine and olomoucine. SCLC cell lines employed are chemoresistant NCI-H417 and DMS153 and the chemosensitive SCLC26A line established at our institution. The CPT analogs exhibiting highest cytotoxicity towards the three SCLC lines tested were SN38 and 9AC, followed by rubitecan, HOCPT, TPT and CPT109. NCI-H417 and DMS153 revealed an approximately 25-fold and 7-fold higher resistance compared to the chemosensitive SCLC26A cell line. Whereas the CDK4/6 inhibitor PD0332991 proved less effective to chemosensitize SCLC cells to CPT analogs, the CDK inhibitors CDK4I, roscovitine and olomoucine gave comparable chemosensitization effects in combination with 9AC, SN38, rubitecan and to a lesser extent with TPT and CPT109, not directly related with topoisomerase mRNA expression. In conclusion, small chemical modifications of the parent CPT structure result in differing cytotoxicities and chemomodulatory effects in combination with CDKIs of the resulting analogs. Full article
(This article belongs to the Special Issue Bioactivity-focused Semi-synthesis in Drug Discovery)
Open AccessArticle Synthesis and Structure-Activity Relationships of Novel Ecdysteroid Dioxolanes as MDR Modulators in Cancer
Molecules 2013, 18(12), 15255-15275; doi:10.3390/molecules181215255
Received: 31 October 2013 / Revised: 30 November 2013 / Accepted: 2 December 2013 / Published: 10 December 2013
Cited by 6 | PDF Full-text (357 KB) | HTML Full-text | XML Full-text
Abstract
Ecdysteroids, molting hormones of insects, can exert several mild, non-hormonal bioactivities in mammals, including humans. In a previous study, we have found a significant effect of certain derivatives on the ABCB1 transporter mediated multi-drug resistance of a transfected murine leukemia cell line. [...] Read more.
Ecdysteroids, molting hormones of insects, can exert several mild, non-hormonal bioactivities in mammals, including humans. In a previous study, we have found a significant effect of certain derivatives on the ABCB1 transporter mediated multi-drug resistance of a transfected murine leukemia cell line. In this paper, we present a structure-activity relationship study focused on the apolar dioxolane derivatives of 20-hydroxyecdysone. Semi-synthesis and bioactivity of a total of 32 ecdysteroids, including 20 new compounds, is presented, supplemented with their complete 1H- and 13C-NMR signal assignment. Full article
(This article belongs to the Special Issue Bioactivity-focused Semi-synthesis in Drug Discovery)

Journal Contact

MDPI AG
Molecules Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
molecules@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Molecules
Back to Top